Search

Home > Lung Cancer Considered > FDA Approval: Repotrectinib, a ROS1 and NTRK inhibitor
Podcast: Lung Cancer Considered
Episode:

FDA Approval: Repotrectinib, a ROS1 and NTRK inhibitor
Category: Science & Medicine
Duration: 00:37:21
Publish Date: 2023-11-30 14:00:16
Description: Lung Cancer Considered host Dr. Stephen Liu moderates a discussion on the November 15, 2023, US FDA approval of repotrectinib for advanced NSCLC with a ROS1 gene fusion based on the single-arm, multi-cohort TRIDENT-1 trial.
Total Play: 0